HUTCHMED closes HMPL-A830 license deal with GSK for territories outside ChinaOct 21PartnershipHMPL-A830Hutchmed
HUTCHMED's HMPL-A830 trial registry posted, detailing 147-participant Phase I/IIa designOct 1Weekly roundup, 2 itemsHMPL-A830HutchmedUpdated
HUTCHMED licenses HMPL-A830 to GSK; source cites both $1.295B and $1.185B totalsSep 3PartnershipHMPL-A830Hutchmed
HUTCHMED posts H1 2026 revenue of $278.3M as China sales rebound and ATTC pipeline advancesJul 30Quarterly updateHutchmed
Hutchmed registers first-in-human Phase I/IIa trial of HMPL-A830 in solid tumorsJul 22Trial updateHMPL-A830Hutchmed